Vogenx Initiates EMERGE, Phase 2b Clinical Trial Evaluating Mizagliflozin For Treatment Of Post-Bariatric Hypoglycemia
Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgeryRALEIGH, NC /
Vogenx started testing a new medicine for people with low blood sugar after weight loss surgery. When a company tests new medicines, it shows they are moving forward with their business plan.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.